Skip to Main Content

Medical pioneers Carl June, Bruce Levine, and Drew Weissman have teamed up to launch a new biotech that hopes to use the industry’s buzziest technologies to boost the beleaguered cell therapy field.

Their new venture, Capstan Therapeutics, launched Wednesday with a combined $165 million in seed and Series A financing.


The company plans to create cell therapies, particularly ones that transform a person’s T cells into cancer-fighting warriors. This type of treatment, called CAR-T, has shown huge potential in treating several different types of cancer, but is notoriously difficult and time-consuming to manufacture, forcing physicians to make gut-wrenching decisions about which patients should get access to the medicine.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.